A novel Lyn-binding peptide inhibitor blocks eosinophil differentiation, survival, and airway eosinophilic inflammation

Tetsuya Adachi, Susan Stafford, Sanjiv Sur, Rafeul Alam

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Receptor antagonists block all receptor-coupled signaling pathways indiscriminately. We introduce a novel class of peptide inhibitors that is designed to block a specific signal from a receptor while keeping other signals intact. This concept was tested in the model of IL-5 signaling via Lyn kinase. We have previously mapped the Lyn-binding site of the IL-5/GM- CSF receptor common β (βe) subunit. In the present study, we designed a peptide inhibitor using the Lyn-binding sequence. The peptide was N-stearated to enable cellular internalization. The stearated peptide blocked the hinding of Lyn to the βe receptor and the activation of Lyn. The lipopeptide did not affect the activation of Janus kinase 2 or its association with βe. The inhibitor blocked the Lyn-dependent functions of IL-5 in vitro (e.g., eosinophil differentiation from stem cells and eosinophil survival). It did not affect eosinophil degranulation. When applied in vivo, the Lyn-binding peptide significantly inhibited airway eosinophil influx in a mouse model of asthma. The lipopeptide had no effect on basophil histamine release or on the proliferation of B cells and T cells. To our knowledge, this is the first report on an inhibitor of IL-5 that blocks eosinophil differentiation, survival, and airway eosinophilic inflammation. This novel strategy to develop peptide inhibitors can be applied to other receptors.

Original languageEnglish (US)
Pages (from-to)939-946
Number of pages8
JournalJournal of Immunology
Volume163
Issue number2
StatePublished - Jul 15 1999

Fingerprint

Eosinophils
Interleukin-5
Inflammation
Peptides
Lipopeptides
Granulocyte-Macrophage Colony-Stimulating Factor Receptors
Janus Kinase 2
Basophils
Histamine Release
Cell Survival
B-Lymphocytes
Phosphotransferases
Stem Cells
Asthma
Binding Sites
T-Lymphocytes

ASJC Scopus subject areas

  • Immunology

Cite this

A novel Lyn-binding peptide inhibitor blocks eosinophil differentiation, survival, and airway eosinophilic inflammation. / Adachi, Tetsuya; Stafford, Susan; Sur, Sanjiv; Alam, Rafeul.

In: Journal of Immunology, Vol. 163, No. 2, 15.07.1999, p. 939-946.

Research output: Contribution to journalArticle

Adachi, Tetsuya ; Stafford, Susan ; Sur, Sanjiv ; Alam, Rafeul. / A novel Lyn-binding peptide inhibitor blocks eosinophil differentiation, survival, and airway eosinophilic inflammation. In: Journal of Immunology. 1999 ; Vol. 163, No. 2. pp. 939-946.
@article{3a5f12a3bb0948ad82ba595cbf81b84a,
title = "A novel Lyn-binding peptide inhibitor blocks eosinophil differentiation, survival, and airway eosinophilic inflammation",
abstract = "Receptor antagonists block all receptor-coupled signaling pathways indiscriminately. We introduce a novel class of peptide inhibitors that is designed to block a specific signal from a receptor while keeping other signals intact. This concept was tested in the model of IL-5 signaling via Lyn kinase. We have previously mapped the Lyn-binding site of the IL-5/GM- CSF receptor common β (βe) subunit. In the present study, we designed a peptide inhibitor using the Lyn-binding sequence. The peptide was N-stearated to enable cellular internalization. The stearated peptide blocked the hinding of Lyn to the βe receptor and the activation of Lyn. The lipopeptide did not affect the activation of Janus kinase 2 or its association with βe. The inhibitor blocked the Lyn-dependent functions of IL-5 in vitro (e.g., eosinophil differentiation from stem cells and eosinophil survival). It did not affect eosinophil degranulation. When applied in vivo, the Lyn-binding peptide significantly inhibited airway eosinophil influx in a mouse model of asthma. The lipopeptide had no effect on basophil histamine release or on the proliferation of B cells and T cells. To our knowledge, this is the first report on an inhibitor of IL-5 that blocks eosinophil differentiation, survival, and airway eosinophilic inflammation. This novel strategy to develop peptide inhibitors can be applied to other receptors.",
author = "Tetsuya Adachi and Susan Stafford and Sanjiv Sur and Rafeul Alam",
year = "1999",
month = "7",
day = "15",
language = "English (US)",
volume = "163",
pages = "939--946",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "2",

}

TY - JOUR

T1 - A novel Lyn-binding peptide inhibitor blocks eosinophil differentiation, survival, and airway eosinophilic inflammation

AU - Adachi, Tetsuya

AU - Stafford, Susan

AU - Sur, Sanjiv

AU - Alam, Rafeul

PY - 1999/7/15

Y1 - 1999/7/15

N2 - Receptor antagonists block all receptor-coupled signaling pathways indiscriminately. We introduce a novel class of peptide inhibitors that is designed to block a specific signal from a receptor while keeping other signals intact. This concept was tested in the model of IL-5 signaling via Lyn kinase. We have previously mapped the Lyn-binding site of the IL-5/GM- CSF receptor common β (βe) subunit. In the present study, we designed a peptide inhibitor using the Lyn-binding sequence. The peptide was N-stearated to enable cellular internalization. The stearated peptide blocked the hinding of Lyn to the βe receptor and the activation of Lyn. The lipopeptide did not affect the activation of Janus kinase 2 or its association with βe. The inhibitor blocked the Lyn-dependent functions of IL-5 in vitro (e.g., eosinophil differentiation from stem cells and eosinophil survival). It did not affect eosinophil degranulation. When applied in vivo, the Lyn-binding peptide significantly inhibited airway eosinophil influx in a mouse model of asthma. The lipopeptide had no effect on basophil histamine release or on the proliferation of B cells and T cells. To our knowledge, this is the first report on an inhibitor of IL-5 that blocks eosinophil differentiation, survival, and airway eosinophilic inflammation. This novel strategy to develop peptide inhibitors can be applied to other receptors.

AB - Receptor antagonists block all receptor-coupled signaling pathways indiscriminately. We introduce a novel class of peptide inhibitors that is designed to block a specific signal from a receptor while keeping other signals intact. This concept was tested in the model of IL-5 signaling via Lyn kinase. We have previously mapped the Lyn-binding site of the IL-5/GM- CSF receptor common β (βe) subunit. In the present study, we designed a peptide inhibitor using the Lyn-binding sequence. The peptide was N-stearated to enable cellular internalization. The stearated peptide blocked the hinding of Lyn to the βe receptor and the activation of Lyn. The lipopeptide did not affect the activation of Janus kinase 2 or its association with βe. The inhibitor blocked the Lyn-dependent functions of IL-5 in vitro (e.g., eosinophil differentiation from stem cells and eosinophil survival). It did not affect eosinophil degranulation. When applied in vivo, the Lyn-binding peptide significantly inhibited airway eosinophil influx in a mouse model of asthma. The lipopeptide had no effect on basophil histamine release or on the proliferation of B cells and T cells. To our knowledge, this is the first report on an inhibitor of IL-5 that blocks eosinophil differentiation, survival, and airway eosinophilic inflammation. This novel strategy to develop peptide inhibitors can be applied to other receptors.

UR - http://www.scopus.com/inward/record.url?scp=0033565287&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033565287&partnerID=8YFLogxK

M3 - Article

C2 - 10395690

AN - SCOPUS:0033565287

VL - 163

SP - 939

EP - 946

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 2

ER -